Clinical research advances in mesenchymal stem cells for the treatment of autoimmune liver diseases
10.3969/j.issn.1001-5256.2023.05.002
- VernacularTitle:间充质干细胞治疗自身免疫性肝病的临床研究进展
- Author:
Wanwan SHI
1
;
Jiandan QIAN
1
;
Guiqiang WANG
1
Author Information
1. Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis, Autoimmune;
Primary Biliary Cholangitis;
Primary Sclerosing Cholangitis;
Mesenchymal Stem Cells
- From:
Journal of Clinical Hepatology
2023;39(5):1004-1009
- CountryChina
- Language:Chinese
-
Abstract:
Due to limited options and modalities for the etiological treatment of autoimmune liver diseases, it is urgent to seek new therapeutic methods for liver autoimmune diseases. As the most common source of cells for stem cell therapy, mesenchymal stem cells (MSCs) play an important role in regulating innate and adaptive immune responses and have been widely used in clinical trials for the treatment of autoimmune diseases and inflammatory diseases. Recent experimental and clinical studies have shown that MSCs and MSC-EVs can inhibit the activation and proliferation of a variety of liver proinflammatory cells (such as Th1, Th17, and M1 macrophages), regulate the differentiation of different subsets of T and B cells, reduce the secretion of proinflammatory cytokines, and promote the proliferation of anti-inflammatory cells, thereby playing an immunoregulatory role. This article reviews the clinical trials of MSCs and MSC-EVs in the treatment of autoimmune liver diseases and their mechanism in regulating immune function and promoting hepatocyte regeneration and briefly describes the potential application and limitations of MSCs and MSC-EVs in clinical practice.
